NEW YORK, March 2, 2022 /PRNewswire/ -- Mind Medicine
(MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), a clinical-stage
biopharmaceutical company developing psychedelic-inspired therapies
for the treatment of brain-based disorders, today announced the
peer-reviewed publication of a study directly comparing the acute
effects of Lysergic Acid Diethylamide (LSD) and psilocybin in
healthy subjects. The data, published in
Neuropsychopharmacology and titled, "Direct comparison of
the acute effects of lysergic acid diethylamide and psilocybin in a
double-blind placebo-controlled study in healthy subjects",
demonstrates that the key differences between LSD and psilocybin
are dose-dependent rather than substance-dependent. These findings
have the potential to assist with dose finding, trial design and
inform future studies evaluating the therapeutic utility of
psychedelics.
![Mindmed logo (PRNewsfoto/Mind Medicine, Inc. (Mindmed)) Mindmed logo (PRNewsfoto/Mind Medicine, Inc. (Mindmed))](https://mma.prnewswire.com/media/996320/Mindmed_Logo.jpg)
"The results in this publication continue to expand our
knowledge of the differences between LSD and psilocybin with regard
to their acute effects, similarities, and dose-equivalence," said
Professor Matthias Liechti M.D.,
University Hospital Basel, principal investigator of the study.
"Although both substances are used as pharmacological tools, there
are no modern studies investigating and directly comparing the
acute effects of these substances within the same clinical study,
using well defined doses and validated psychometric tools.
Together, these results suggest that 20 mg psilocybin is equivalent
to 100 μg LSD, and 30 mg psilocybin is equivalent to 150 μg LSD,
making the dose equivalence of LSD to psilocybin approximately
1:200. Strikingly, there were no qualitative differences in altered
states of consciousness across substances, except that the duration
of action was shorter for psilocybin."
Miri Halperin Wernli, Ph.D.,
Executive President of MindMed, added, "LSD and psilocybin have
recently become promising candidates for the treatment of various
psychiatric and neurologic disorders, and thus a deeper
understanding of their differential subjective effects in humans is
needed. This study brings us one step closer to maximizing the
therapeutic potential of these molecules, by providing valuable
dose finding context and enabling more direct comparisons when
interpreting clinical results. These learnings will help guide our
rapidly advancing clinical development program, and we look forward
to providing updates as we work to bring the benefits of
psychedelic-inspired medicines to patients struggling with
brain-based disorders."
In this double-blind, randomized, placebo-controlled, crossover
design, researchers evaluated twenty-eight healthy participants who
underwent five 25-hour sessions and received placebo, LSD (100 and
200 µg), and psilocybin (15 and 30 mg). Test days were separated by
at least 10 days. Outcome measures included self-rating scales for
subjective effects, autonomic effects, adverse effects, effect
durations, plasma levels of brain-derived neurotrophic factor
(BDNF), prolactin, cortisol, and oxytocin, and
pharmacokinetics.
The study characterized the effects of LSD and psilocybin at two
different doses and showed that both doses of LSD and the high dose
of psilocybin produced qualitatively and quantitatively similar
subjective effects, indicating that alterations of mind do not
differ beyond the effect duration. As expected, the 200 µg LSD dose
induced higher ratings of ego-dissolution, anxiety, as well as
impairments in control and cognition, compared to the 100 µg LSD
dose. The 200 µg LSD dose increased ratings of ineffability
significantly more than 30 mg psilocybin. Interestingly, LSD at
both doses had clearly longer effect durations than psilocybin.
Taken together, these results suggest that the 20 mg psilocybin
dose is likely equivalent to the 100 µg LSD dose. Beyond subjective
effects, both LSD and psilocybin showed comparable cardio-stimulant
properties, assessed by the rate-pressure product.
MindMed retains executive rights to data from this investigator
initiated study conducted at the University Hospital Basel.
About MindMed
MindMed is a clinical-stage psychedelic medicine biotech company
that seeks to discover, develop and deploy psychedelic-inspired
medicines and therapies to address addiction and mental illness.
The Company is assembling a compelling drug development pipeline of
innovative treatments based on psychedelic substances including
psilocybin, LSD, MDMA, DMT and an ibogaine derivative, 18-MC. The
MindMed executive team brings extensive biopharmaceutical
experience to MindMed's approach to developing the next generation
of psychedelic-inspired medicines and therapies.
MindMed trades on the NASDAQ under the symbol MNMD and on the
Canadian NEO Exchange under the
symbol MMED.
Forward-Looking Statements
Certain statements in this news release related to the Company
constitute "forward-looking information" within the meaning of
applicable securities laws and are prospective in nature.
Forward-looking information is not based on historical facts, but
rather on current expectations and projections about future events
and are therefore subject to risks and uncertainties which could
cause actual results to differ materially from the future results
expressed or implied by the forward-looking statements. There are
numerous risks and uncertainties that could cause actual results
and the Company's plans and objectives to differ materially from
those expressed in the forward-looking information, including
history of negative cash flows; limited operating history;
incurrence of future losses; availability of additional capital;
lack of product revenue; compliance with laws and regulations;
difficulty associated with research and development; risks
associated with clinical trials or studies; heightened regulatory
scrutiny; early stage product development; clinical trial risks;
regulatory approval processes; novelty of the psychedelic inspired
medicines industry; as well as those risk factors discussed or
referred to herein and the risks described under the headings "Risk
Factors" in the Company's filings with the securities regulatory
authorities in all provinces and territories of Canada which are available under the Company's
profile on SEDAR at www.sedar.com and with the U.S. Securities
and Exchange Commission on EDGAR at www.sec.gov.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/mindmed-announces-publication-of-study-comparing-the-acute-effects-of-lysergic-acid-diethylamide-and-psilocybin-in-healthy-subjects-301493703.html
SOURCE Mind Medicine (MindMed) Inc.